Medicare Enrolled
Dr. Mihran Shirinian, M.D.
Hematology & Oncology · Glendale, CA
Practice pattern: Mixed Practice
— Diverse clinical practice across multiple procedure types
Consulting-driven
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Shirinian from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Shirinian?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Shirinian
Dr. Mihran Shirinian is a hematology & oncology specialist in Glendale, CA, with 19 years of NPI registration. Based on federal Medicare data, Dr. Shirinian performed 148,770 Medicare services across 4,624 unique beneficiaries.
Between the years covered by Open Payments, Dr. Shirinian received a total of $27,563 from 36 pharmaceutical and/or device companies across 139 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in hematology & oncology. The majority of payments are for consulting, which typically reflects recognized clinical expertise sought by manufacturers. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Shirinian is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 19 years in practice
▲ Top 4% volume in CA
$27,563 industry payments
Medicare Practice Summary
Medicare Utilization ↗148,770
Medicare services
Top 4% in CA for hematology & oncology
4,624
Unique beneficiaries
$8
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~7,830 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Pembrolizumab injection (Keytruda) | 29,601 | $6 | $12 |
| Filgrastim injection (Zarxio) for white blood cells An injection of the biosimilar medication filgrastim-sndz (Zarxio) with a dosage of 1 microgram. |
24,300 | $0 | $2 |
| Oxaliplatin chemotherapy injection This procedure involves the administration of oxaliplatin, a chemotherapy medication, via injection. The dosage specified is 0.5 mg. |
23,900 | $0 | $2 |
| Anti-nausea injection (ondansetron/Zofran) | 16,996 | $0 | $3 |
| Bevacizumab injection, 10 mg Administration of a 10 mg dose of bevacizumab medication via injection. |
11,629 | $0 | $0 |
| Iron sucrose injection (Venofer) An injection of iron sucrose used to replenish iron levels in the body. |
9,500 | $0 | $5 |
| Blood draw (venipuncture) Insertion of a needle into a vein to collect a blood sample. |
3,769 | $8 | $20 |
| Complete blood count (CBC) with differential An automated laboratory test that measures the levels of red blood cells, white blood cells, and platelets in the blood, including a breakdown of the different types of white blood cells. |
3,731 | $8 | $25 |
| Dexamethasone injection (steroid) An injection of dexamethasone sodium phosphate, a corticosteroid medication, administered in a dose of 1 milligram. |
3,446 | $0 | $5 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
1,811 | $101 | $210 |
| Injection, leucovorin calcium, per 50 mg | 1,684 | $3 | $50 |
| Epoetin alfa injection (Procrit) for anemia An injection of epoetin alfa containing 1000 units for use in patients not on end-stage renal disease (ESRD) dialysis. |
1,560 | $5 | $25 |
| Normal saline infusion, 500 ml Administration of sterile normal saline solution through an intravenous line. This procedure involves the infusion of a 500 ml unit of the solution. |
1,259 | $1 | $20 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
1,244 | $77 | $140 |
| Additional hour of intravenous chemotherapy This code represents the administration of chemotherapy medication into a vein for each additional hour beyond the initial period. |
1,217 | $25 | $100 |
| Hospital follow-up visit, moderate complexity Follow-up hospital visit for an existing patient involving moderate medical decision making. The visit requires at least 35 minutes of time spent on the date of service. |
1,198 | $66 | $110 |
| Fluorouracil injection, 500 mg Administration of a 500 mg dose of fluorouracil medication via injection. |
1,153 | $2 | $10 |
| Hospital follow-up visit, high complexity Subsequent hospital inpatient or observation care for an existing patient involving high-level medical decision making, with at least 50 minutes total time on the date of the encounter. |
1,137 | $100 | $150 |
| Additional hour of intravenous hydration This code represents each additional hour of intravenous fluid administration beyond the initial hour. It is used to bill for extended hydration therapy. |
1,023 | $11 | $80 |
| Epoetin alfa injection (Retacrit) for anemia An injection of a biosimilar form of epoetin alfa used for non-end-stage renal disease purposes. The dose administered is 1000 units. |
1,000 | $6 | $25 |
| Office visit, established patient (10-19 min) An office visit for an existing patient lasting 10 to 19 minutes. The visit involves medical evaluation and management of the patient's condition. |
920 | $47 | $110 |
| Additional hour of intravenous infusion This code represents each additional hour of intravenous infusion beyond the initial hour for therapy, prevention, or diagnosis. |
755 | $18 | $80 |
| Intravenous chemotherapy infusion, 1 hour or less Administration of chemotherapy medication directly into a vein. The procedure takes one hour or less to complete. |
664 | $118 | $300 |
| Normal saline infusion, 1000 cc Administration of 1000 cc of normal saline solution into a vein. This procedure involves the intravenous delivery of a sterile saltwater solution. |
588 | $2 | $20 |
| Intravenous hydration infusion, 31-60 minutes Administration of fluids into a vein to maintain hydration. This procedure involves an infusion lasting between 31 and 60 minutes. |
548 | $30 | $120 |
| Carboplatin chemotherapy injection, 50 mg Administration of a 50 mg dose of carboplatin, a chemotherapy medication, via injection. |
540 | $2 | $60 |
| Nursing facility visit, moderate complexity A follow-up visit by a healthcare provider at a nursing facility for an established patient. The visit involves moderate medical decision making and takes at least 30 minutes. |
516 | $90 | $150 |
| Additional sequential IV infusion, 1 hour or less This code represents an additional intravenous infusion administered sequentially to a primary infusion. It covers the administration time of one hour or less. |
479 | $26 | $100 |
| Office visit, established patient, complex (40-54 min) An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter. |
471 | $149 | $300 |
| Drug injection, under skin or into muscle A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle. |
423 | $12 | $35 |
| Intravenous infusion of new drug or substance, 1 hour or less This procedure involves administering a new medication or substance directly into a vein through an existing access site. The infusion is completed within one hour or less. |
299 | $59 | $150 |
| Zoledronic acid injection, 1 mg An injection of zoledronic acid administered at a dose of 1 mg. |
252 | $7 | $100 |
| Normal saline infusion, 250 cc Administration of 250 cubic centimeters of normal saline solution into a vein. This procedure involves the intravenous delivery of a sterile saltwater fluid. |
176 | $1 | $20 |
| Initial hospital admission, high complexity Initial hospital inpatient or observation care for a new patient involving high-level medical decision making, with at least 75 minutes total time on the date of the encounter. |
133 | $143 | $350 |
| Intravenous push injection of new drug or substance A healthcare provider injects a new medication or substance directly into a vein using a push technique. |
127 | $51 | $150 |
| IV chemotherapy initiation with community continuation Initiation of an intravenous chemotherapy infusion in a clinic using clinic supplies, with continuation of the infusion in a community setting such as home or assisted living. |
124 | $156 | $300 |
| Intravenous infusion, 1 hour or less Administration of medication or fluid directly into a vein for therapeutic, preventive, or diagnostic purposes. The procedure lasts one hour or less. |
120 | $56 | $200 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 119 | $121 | $360 |
| New patient office visit, complex (60-74 min) | 113 | $176 | $350 |
| Subcutaneous or intramuscular chemotherapy injection This procedure involves administering anti-cancer hormonal medication through an injection into the tissue under the skin or into a muscle. |
104 | $30 | $100 |
| Vitamin B-12 injection An injection of vitamin B-12 (cyanocobalamin) with a dose of up to 1000 mcg. |
72 | $1 | $20 |
| Nursing facility visit, high complexity A follow-up visit by a healthcare provider at a nursing facility for an established patient. The visit involves a high level of medical decision making and takes at least 45 minutes. |
69 | $128 | $200 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
3.3% high complexity
85.8% medium
10.9% routine
Industry Payment Transparency
Open Payments through 2024 ↗$27,563
Total received (2018-2024)
Avg $3,938/year across 7 years
Top 16% in CA for hematology & oncology
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
36
Companies
139
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Consulting
Expert advisory fees, typically reflecting recognized clinical expertise
$13,652 (49.5%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$8,531 (31.0%)
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$5,380 (19.5%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$3,863
2023
$2,024
2022
$176
2021
$3,805
2020
$6,871
2019
$5,832
2018
$4,992
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
Novartis Pharmaceuticals Corporation
$1,575
PFIZER INC.
$1,476
AstraZeneca Pharmaceuticals LP
$141
Merck Sharp & Dohme LLC
$116
Incyte Corporation
$100
Astellas Pharma US Inc
$95
Pulmonx Corporation
$79
ABBVIE INC.
$63
Janssen Scientific Affairs, LLC
$59
E.R. Squibb & Sons, L.L.C.
$42
Myriad Genetic Laboratories, Inc.
$34
Adaptive Biotechnologies Corporation
$29
JAZZ PHARMACEUTICALS INC.
$23
Takeda Pharmaceuticals U.S.A., Inc.
$16
Deciphera Pharmaceuticals Inc.
$14
Top 3 companies account for 82.6% of 2024 payments
All-time payments by company (2018-2024) ›
PFIZER INC.
$3,695
Exelixis Inc.
$3,483
Takeda Pharmaceuticals U.S.A., Inc.
$2,964
Genentech USA, Inc.
$2,579
TESARO, Inc.
$2,358
AstraZeneca Pharmaceuticals LP
$2,083
Stemline Therapeutics Inc.
$1,620
Novartis Pharmaceuticals Corporation
$1,575
Innate Pharma, Inc
$1,200
Genentech, Inc.
$1,200
Gilead Sciences, Inc.
$1,012
Immunomedics, Inc.
$1,000
BeiGene, Ltd.
$450
Incyte Corporation
$435
Merck Sharp & Dohme LLC
$276
Astellas Pharma US Inc
$194
Amgen Inc.
$188
Dova Pharmaceuticals
$162
E.R. Squibb & Sons, L.L.C.
$135
Seagen Inc.
$124
Janssen Biotech, Inc.
$113
Merck Sharp & Dohme Corporation
$98
Janssen Scientific Affairs, LLC
$89
Myriad Genetic Laboratories, Inc.
$82
Seattle Genetics, Inc.
$80
Pulmonx Corporation
$79
ABBVIE INC.
$63
Janssen Pharmaceuticals, Inc
$40
EMD Serono, Inc.
$39
Adaptive Biotechnologies Corporation
$29
Myovant Sciences Inc.
$29
JAZZ PHARMACEUTICALS INC.
$23
Mirati Therapeutics, Inc.
$21
GlaxoSmithKline, LLC.
$18
Deciphera Pharmaceuticals Inc.
$14
MEDIVATION FIELD SOLUTIONS LLC
$10
Top 3 companies account for 36.8% of all-time payments
Associated products mentioned in payments ›
ADCETRIS · BAVENCIO · BOSULIF · BRUKINSA · CHARTIS CATHETER · Cabometyx · Doptelet · ELAHERE · ELIQUIS · ELREXFIO · ENHERTU · ERLEADA · FRUZAQLA · IBRANCE · IMBRUVICA · INLYTA · KEYTRUDA · KISQALI · KRAZATI · LUMAKRAS · LYNPARZA · Lumoxiti · MYRISK · NINLARO · Neulasta · Nplate · OPDIVO · OPDUALAG · ORGOVYX · Orserdu · QINLOCK · SUTENT · TALZENNA · TECENTRIQ · Trodelvy · XARELTO · XTANDI · Xtandi · ZEJULA · ZEPZELCA · clonoSEQ · myRisk
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
The majority of payments (50%) are consulting fees, which typically reflect recognized clinical expertise sought by manufacturers.
Geographic Context
Hematology & oncology specialists within 10 mi
369
Per 100K population
3.7
County median income
$87,760
Nearest hospital
GLENDALE ADVENTIST MEDICAL CENTER
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Shirinian is a mixed practice specialist, with above-average Medicare volume (top 4% in CA), with consulting-driven industry engagement in the top 16% of CA peers, with 19 years of NPI registration.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Shirinian experienced with pembrolizumab injection (keytruda)?
Based on Medicare claims data, Dr. Shirinian performed 29,601 pembrolizumab injection (keytruda) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Shirinian receive payments from pharmaceutical companies?
Yes. Dr. Shirinian received a total of $27,563 from 36 companies across 139 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Shirinian's costs compare to other hematology & oncology specialists in Glendale?
Dr. Shirinian's average Medicare payment per service is $8. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Shirinian) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Hematology & Oncology Specialists in Glendale
Browse hematology & oncology specialists in Glendale ranked by procedure volume and transparency data.
Highest volume
Top Hematology & Oncology Specialists in CA
Hematology & oncology specialists ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Hematology & Oncology Specialists in CA
Which CA hematology & oncology specialists receive the most from drug and device companies.
By company
PFIZER INC. Payments to Doctors
See all physicians who received payments from PFIZER INC.
By company
Exelixis Inc. Payments to Doctors
See all physicians who received payments from Exelixis Inc.
By company
Takeda Pharmaceuticals U.S.A., Inc. Payments to Doctors
See all physicians who received payments from Takeda Pharmaceuticals U.S.A., Inc.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology